Talentmark Top Life Science Company in the 2012 Institute of Interim Management Survey
London, 6th August 2012:Talentmark is delighted to announce that it is the only interim service provider dedicated to life sciences to reach the top 25 in the Institute of Interim Management’s 2012 Survey.
Entering the survey for the first time this year, Talentmark has excelled by reaching twenty-second place in the poll of over 2500 interim managers and associated professionals.
Talentmark has been servicing the global life science industry since 1971 and in 2011 the company formed a separate division under the leadership of Dafydd Wright, a seasoned pharmaceutical interim management specialist.
“We’re absolutely delighted to have attained this position in the IIM 2012 Survey,” comments Dafydd Wright, Manager for Talentmark’s Interims. “Talentmark has been making great strides forward with our Interim Management service and our position in this survey reflects the positive way that the market has judged our efforts. We work our networks hard to identify senior level candidates who are able to make a real difference to client organisations and we ensure that we know these candidates really well. Our ethos is that focusing on the right people rather than on the scale of one’s database creates excellent results, and, combined with Talentmark’s 40 years of industry experience, enables us to make informed and experienced recommendations. It’s effective for the independents we represent too. Executives know that if they join our portfolio, we will be proactive in highlighting their credentials when suitable projects develop.”
David Nolan, Talentmark’s Managing Director comments, “It’s fantastic that the efforts of our interim management team have been so well recognised by the interim community in this survey. Dafydd is leading a team that is very focused on identifying the right people for client organisations, both in terms of their expertise and cultural fit. This takes a lot of research and consideration but provides clients with a high level, manageable solution to their business needs.”
The Ambiguity of the MSL
The Attraction of Biosimilar Companies